A comprehensive view of Galderma Laboratories LP. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Galderma delivers a strong start to the year with record Q1 net sales of over US$1B and 12.4% year-over-year growth, primarily driven by volume
Published: April 24, 2024 by Business Wire
Galderma Announces Full Exercise of Over-Allotment Option
Published: March 26, 2024 by Business Wire
Galderma prices IPO at CHF 53/share and will start trading on the SIX Swiss Exchange tomorrow
Published: March 21, 2024 by Business Wire
Galderma CEO discusses 'landmark' 2023 performance; CEO expects continued momentum in 2024, leveraging pure-play dermatology focus, strong positions of Cetaphil, Dysport, Sculptra and Restylane brands, global omnichannel execution, education and services
Published: March 15, 2024 by CosmeticsDesign.com (US)
Galderma Launches IPO on the SIX Swiss Exchange and Sets Price Range
Published: March 13, 2024 by Business Wire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count